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Abstract 29 
Background and purpose: Small conductance Ca
2+
-activated K
+
 (KCa2) channels 30 
represent a promising atrial-selective target for treatment of atrial fibrillation (AF). 31 
Here, we establish the mechanism of KCa2 inhibition by the new compound AP14145. 32 
Experimental approach: Using site directed mutagenesis binding determinants for 33 
AP14145 inhibition were explored. AP14145 selectivity and mechanism of action were 34 
investigated by patch clamp recordings of heterologously expressed KCa2 channels. The 35 
biological efficacy of AP14145 was assessed by measuring atrial effective refractory 36 
period (AERP) prolongation in anaesthetised rats and a beam walk test was performed 37 
in mice to determine acute CNS related effects of the drug. 38 
Key results: AP14145 was found to be an equipotent negative allosteric modulator of 39 
KCa2.2 and KCa2.3 channels (IC50 = 1.1 ± 0.3 µM L
-1
). The presence of AP14145 (10 40 
µM L
-1
) increased the EC50 of Ca
2+
 on KCa2.3 from 0.36 ± 0.02 µM L
-1
 to 1.2 ± 0.1 µM 41 
L
-1
. The inhibitory effect strongly depended on two amino acids, S508 and A533. 42 
AP14145 concentration-dependently prolonged AERP in rats. Moreover, AP14145 (10 43 
mg kg
-1
) did not trigger any apparent CNS effects in mice. 44 
Conclusion and implications: AP14145 is a negative allosteric modulator of KCa2.2 45 
and KCa2.3 that shifts the calcium dependence of channel activation, an effect strongly 46 
dependent on two identified amino acids. AP14145 prolongs AERP in rats and does not 47 
trigger any acute CNS effects in mice. The understanding of how KCa2 inhibition is 48 
accomplished at the molecular level will help future development of drugs targeting 49 
KCa2 channels. 50 
 51 
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Introduction 58 
Small conductance calcium-activated potassium channels (KCa2.1, KCa2.2 and KCa2.3 59 
channels) are widely distributed in humans (Chen et al., 2004), where they serve 60 
important roles such as contributing to the afterhyperpolarization in neurons (Pedarzani 61 
et al., 2005),  the endothelium-derived hyperpolarization (Milkau et al., 2010) or the late 62 
repolarization phase in cardiomyocytes (Li et al., 2009). These channels are 63 
constitutively associated to calmodulin, which binds intracellular calcium and activates 64 
KCa2 (Adelman, 2016). Since cloning of the channels 20 years ago (Köhler et al., 1996), 65 
they have piqued the interest of pharmacologists in different therapeutic areas. Although 66 
at the beginning most of the efforts were focused on the CNS and the treatment of 67 
neurodegenerative and psychiatric diseases (Lam et al., 2013), the therapeutic potential 68 
of KCa2 channels rapidly spread to other areas (Wulff et al., 2007). Currently, one of the 69 
most promising therapeutic opportunities for KCa2 channel modulation seems to be in 70 
cardiovascular diseases, more specifically in atrial fibrillation (AF).  71 
AF is the most common type of cardiac arrhythmia and it is considered one of the 72 
largest public health problems in developed countries (Zoni-Berisso et al., 2014). The 73 
disease is characterized by rapid uncoordinated activation of the atria, resulting in 74 
reduced ventricular filling and blood stasis in atria, which predisposes to heart failure 75 
and thromboembolic stroke (Nattel, 2002). Unfortunately, current rhythm therapy is 76 
only moderately effective and may trigger serious non cardiac as well as ventricular 77 
adverse effects (Waks and Zimetbaum, 2017). 78 
KCa2 channels are considered a promising new target for AF treatment for several 79 
reasons. First, the functional role of KCa2.2 and KCa2.3 channels appears to be greater in 80 
the atria as compared to ventricles which may help avoiding undesired ventricular 81 
adverse effects (Diness et al., 2015). Second, KCa2 channel inhibition prolongs the atrial 82 
effective refractory period (AERP, Diness et al., 2010), a pharmacological strategy that 83 
has successfully been used in the development of other class III antiarrhythmic drugs 84 
(Schmitt et al., 2014). Furthermore, common variants of the genes that encode KCa2.2 85 
and KCa2.3 have been associated with atrial fibrillation (Ellinor et al., 2010; 86 
Christophersen et al., 2017). 87 
The first described negative allosteric modulator was NS8593 (Fig 1), a chiral 2-88 
aminobenzimidazole derivative able to inhibit KCa2 channels at nanomolar 89 
concentrations with no subtype selectivity (Strøbæk et al., 2006; Sørensen et al., 2008). 90 
The negative modulation of NS8593 relies in the compound’s ability to increase Ca2+ 91 
EC50 for KCa2 activation and its binding site has been found to be in the inner pore 92 
vestibule of the channel (Jenkins et al., 2011).  93 
KCa2 channels are widely expressed in the CNS (Stocker and Pedarzani, 2000) and 94 
therefore one of the challenges encountered during the development of compounds 95 
targeting peripheral KCa2 is potential CNS mediated adverse effects (Habermann, 1984). 96 
It is thus important to develop compounds with reduced blood brain barrier penetrance 97 
in order to avoid possible adverse effects. In this work, we present a novel KCa2 98 
negative allosteric modulator, AP14145 (Fig 1), a structurally close analogue of 99 
NS8593 designed to inhibit specifically peripheral KCa2 channels by preventing its entry 100 
in the CNS. In contrast to NS8593, it does not appear to have any immediate CNS 101 
effects when dosed to rodents and therefore represents a new and improved tool 102 
compound for studying KCa2 channel inhibition in rodents in vivo. 103 
 104 
Methods 105 
Molecular biology 106 
rKCa2.3 WT (wild type) and rKCa2.3 S508T A533V were inserted in pXOON plasmids. 107 
The rKCa2.3 NS8593 insensitive mutant was obtained by introducing the double point 108 
mutation to the WT rKCa2.3 with the oligonucleotides 109 
CCATAGCCAATggtAAGGAACGTGATG for S508T and 110 
CATCATGGGTgtaGGCTGCACTGCCCTC for A533V, using PfuUltra II Fusion 111 
polymerase (Agilent, USA) and T4 ligase (New England Biolabs, USA). Note that S508 112 
and A533 on the rKCa2.3 are the equivalent positions of S507 and A532 on the hKCa2.3 113 
channel. Competent E. coli were transformed using an aliquot of the mutagenesis 114 
product by thermic shock and the plasmid DNA was purified using standard methods. 115 
The hKCa3.1 T250S V275A mutant was kindly donated by Dorte Strøbæk. All 116 
constructs were verified by sequencing. 117 
Cell culture and cell preparation 118 
To study the effect of AP14145 on the hKCa1.1 and hKCa2.x channels we used four 119 
different stable HEK293 cell lines expressing hKCa1.1, hKCa2.1, hKCa2.2 or hKCa2.3 120 
channels obtained from NeuroSearch A/S (Ballerup, Denmark). The cell lines were 121 
established as described in Strøbæk et al., 2004. For the identification of the binding 122 
determinants of AP14145, wild-type HEK293 cells were transiently co-transfected with 123 
rKCa2.3 WT, rKCa2.3 S508T A533V, hKCa3.1 WT or hKCa3.1 T250S V275A and 0.1 µg 124 
of eGFP plasmid DNA using standard Lipofectamine™ (Thermo Fisher, USA) 125 
protocols. Between one or two days after the transfection, patch clamp experiments 126 
were conducted. The cells were cultured in Dulbecco’s modified Eagle’s medium 127 
(DMEM1965, Thermo Fisher, USA) supplemented with 26.2 mM L
-1
 NaHCO3, 25 mM 128 
L
-1
 HEPES, 10 ml L
-1
 Glutamax (Gibco, USA), 10 % foetal bovine serum (Biowest, 129 
France) and 100 U ml
-1
 of penicillin/streptomycin (Sigma, Germany). In the case of the 130 
stable cell lines, 100 µg ml
-1
 geneticin (Gibco, USA) were added to the medium. On the 131 
day of the experiment, cells were detached from the flask using 1 ml of Detachin™ 132 
(Amsbio, United Kingdom). After being washed with free calcium and magnesium PBS 133 
the cells were plated on 0.5 mm Ø coverslips. In the case of inside-out patch clamp, the 134 
coverslips were treated overnight at 37ºC with 50 mg ml
-1
 poly-L-lysine (Sigma, 135 
Germany) to get firmer cell attachment.  136 
Solutions and drugs 137 
KCa2 and KCa3.1 patch-clamp experiments were conducted using symmetrical K
+
 138 
solutions. The extracellular solution contained 0.1 mM L
-1
 CaCl2, 3 mM L
-1
 MgCl2, 154 139 
mM L
-1
 KCl, 10 mM L
-1
 HEPES and 10 mM L
-1
 glucose (pH = 7.4 and 285 - 295 140 
mOsm). The intracellular solution contained 8.106 mM L
-1
 CaCl2 (final free Ca
2+
 141 
concentration of 400 nM L
-1
), 1.167 mM L
-1
 MgCl2, 10 mM L
-1
 EGTA, 154 mM L
-1
 142 
KCl, 10 mM L
-1
 HEPES, 31.25/10 mM L
-1
 KOH/EGTA and 15 mM L
-1
 KOH (pH = 143 
7.2). In addition, to study the activation of the channel with or without the presence of 144 
AP14145 we used a range of intracellular solutions containing different free Ca
2+
 145 
concentrations (0.01 - 30 µM L
-1
). The composition of these intracellular solutions was 146 
determined as described in Strobaek et al., 2006.  147 
For KCa1.1 the extracellular solution contained 2 mM L
-1 
CaCl2, 1 mM L
-1
 MgCl2, 145 148 
mM L
-1
 NaCl, 4 mM L
-1
 KCl, 10 mM L
-1
 HEPES and 10 mM L
-1
 glucose (pH = 7.4 and 149 
285 - 295 mOsm). The intracellular solution contained 5.374 mM L
-1
 CaCl2 (final free 150 
Ca
2+
 concentration of 100 nM L
-1
), 1.75 mM L
-1
 MgCl2, 120 mM L
-1
 KCl, 10 mM L
-1
 151 
HEPES, 31.25/10 mM L
-1
 KOH/EGTA (pH = 7.2). 152 
The osmolarity of the intracellular solutions was adjusted using sucrose (Sigma, 153 
Germany) to match the extracellular solutions. 154 
AP14145 (N-(2-{[(1R)
-1
-[3-(trifluoromethyl)phenyl]ethyl]amino}
-1
H
-1
,3-benzodiazol-4-155 
yl)acetamide) was synthetized by Syngene (India) as described in WO 2013104577 A1. 156 
For in vitro experiments, AP14145 was solubilized in pure DMSO (Sigma-Aldrich, 157 
Germany) at 10 mM L
-1
 stock solutions. These stock solutions were stored at -20°C and 158 
aliquots were solubilized at the desired concentration on the day of the experiment. For 159 
in vivo experiments, 5 mg ml
-1
 AP14145 were dissolved in a vehicle consisting of 50% 160 
polyethylene glycol (PEG) 400 (Merck, Germany) and 50% sterile saline (PanReac 161 
AppliChem, Germany) for infusion and the solution was sterile filtered (Nalgene, Rapid 162 
flow 90 mM L
-1
 filter unit, Thermo Scientific, USA) before use. The KCa1.1 selective 163 
inhibitor paxilline was purchased from Sigma-Aldrich (Germany). 164 
Electrophysiology 165 
Patch clamp recordings were made using a HEKA EPC9 amplifier and the Patchmaster 166 
software (HEKA Elektronik, Germany) at room temperature. Patch pipettes were pulled 167 
using a horizontal DMZ Universal Puller (Zeitz, Germany) with resistances of 2.5 ± 0.1 168 
MΩ for whole-cell patch clamp and 2.2 ± 0.6 MΩ for inside-out patch clamp. KCa2 and 169 
KCa3.1 currents were elicited every 2 seconds using a 200 ms voltage ramps ranging -80 170 
mV to +80 mV from a holding potential of 0 mV. KCa1.1 currents were elicited every 2 171 
seconds using a 200 ms voltage ramps ranging -80 mV to +50 mV from a holding 172 
potential of 0 mV. Data were sampled at 10 kHz. Series resistance values were 5.4 ± 0.6 173 
MΩ with 80% of compensation. Two Bessel filters of 10 kHz and 2.9 kHz were used to 174 
avoid background noise.  175 
Plasma Protein Binding 176 
Plasma protein binding (PPB) was experimentally determined by Syngene International 177 
(India) in rat plasma using rapid equilibrium dialysis. 178 
Ex vivo experiments 179 
Ex vivo and in vivo experiments were performed under a license from the Danish 180 
Ministry of justice (license No 2013
-1
5-2934/00964) and in accordance with the Danish 181 
guidelines for animal experiments according to the European Commission Directive 182 
86/609/EEC. The animals were housed in groups of 2-4 in high-top cages with bedding 183 
(wood shavings) and under constant climatic conditions (22°C) at the Department of 184 
Experimental Medicine, University of Copenhagen. The animals were kept at a 12 hour 185 
light-dark cycle with ad libitum access to clean water and standard laboratory rodent 186 
diet. 187 
Isolated perfused heart preparation 188 
Rats express KCa2 channels in the atria, and have previously been used to study the 189 
effect of KCa2 inhibition on atrial refractoriness. Male Sprague-Dawley rats (250 - 350 190 
g, 1-3 months old, Janvier Labs, France) were anaesthetized with fentanyl‐midazolam 191 
mixture, 5 mg ml
-1
 dose 0.3 mL/100 g BW, s.c. A tracheotomy was performed in the 192 
ventilated rat. The aorta was cannulated and the heart was excised, and connected to a 193 
Langendorff retrograde perfusion setup (Hugo Sachs Elektronik, Harvard Apparatus 194 
GmbH, Germany). The heart was retrogradely perfused with Krebs–Henseleit buffer (in 195 
mM L
-1
: NaCl 120.0, NaHCO3 25.0, KCl 4.0, MgSO4 0.6, NaH2PO4 0.6, CaCl2 2.5, 196 
Glucose 11.0, saturated with 95% O2 and 5% CO2, 37°C, pH 7.4) at a constant 197 
perfusion pressure of 80 mmHg. The electrical activity of the heart was measured by 198 
volume conducted electrocardiograms (ECGs) and the atrial epicardial monophasic 199 
action potentials by an electrode on the right atrium. The signal was sampled at 1 kHz 200 
(PowerLab systems, ADInstruments, UK) and monitored by using LabChart 7 software 201 
(ADInstruments, UK). The hearts were immersed into a temperature‐controlled and 202 
carbonated bath containing Krebs–Henseleit buffer. A bipolar pacing electrode was 203 
placed on the right atria in order to stimulate the heart and measure the AERP, which 204 
was defined as the longest S1-S2 interval failing to elicit an action potential. The AERP 205 
was measured every five minutes by applying electrical stimulation (2 times rheobase) 206 
with a fixed interval of 133 ms (S1 stimulation) and for every 10
th
 beat an extra stimulus 207 
(S2 stimulation) was applied with 1 ms increments.  208 
Baseline recordings were made for at least 20 minutes and continued until the ECG 209 
morphology and AERP recording were stable. After the baseline recording, four 20-210 
minute episodes followed in which, the heart, was perfused with: 1) 1 µM L
-1
 paxilline 211 
2) 3 µM L
-1
 paxilline 3) washout 4) 10 µM L
-1
 AP14145 and AERP measurements were 212 
performed every fifth minute. Measurements after 20 minutes of drug perfusion or 213 
washout were used for statistical analysis.  214 
In vivo experiments 215 
Closed chest recording of atrial refractoriness in rats 216 
A total of 18 1-3 months old male Sprague-Dawley rats (Janvier, France) weighing 400-217 
550 g were anesthetized and randomly divided in three groups: one group receiving 218 
AP14145 as bolus injections (n=6), a time matched control group receiving vehicle as 219 
bolus injections (n=6), and a group receiving AP14145 as a constant-rate infusion 220 
(n=6). The rats were anaesthetized with 3 % isofluran/oxygen and an intravenous 221 
catheter was placed in the femoral vein for drug injection. Needle ECG electrodes were 222 
placed in each limb for ECG recordings (ADinstruments, UK). The temperature of the 223 
rats was monitored and kept stable during the experiment with a heating lamp (37 
o
C). 224 
A catheter with eight electrodes (Millar Inc., US) was placed in the right atrium of an 225 
anaesthetized rat via the jugular vein. Two of the electrodes were used to pace the 226 
atrium and six electrodes were used to measure the electrical activity in the atrium. This 227 
combination allows measurements of the AERP and the changes in AERP as a 228 
consequence of injection of the test compound. Once the experiment was completed, 229 
rats were euthanized by a mixture of 200 mg ml
-1
 pentobarbital and 20 mg ml
-1 230 
lidocaine hydrochloride (Glostrup Apotek, Denmark) i.v. injection. Since the risk of 231 
placebo effect and subjective interpretation of the results was inexistent or minimal, no 232 
blinding was used. 233 
Measurement of AERP  234 
Each experiment lasted for at least 60 minutes and was divided into three 20-minutes 235 
episodes. During the entire experiment the ECG was monitored. The AERP was 236 
measured by applying electrical stimulation (5 times rheobase) with a fixed interval of 237 
120 ms (S1 stimulation) and for every 10th beat an extra stimulus (S2 stimulation) was 238 
applied with 1 ms increments. The AERP was defined as the longest S1-S2 interval 239 
failing to elicit an action potential. Between the AERP recordings, the heart remained 240 
unpaced. Baseline AERP recordings with no compound present were made every 5th 241 
minute for 20 minutes before adding test compound. 242 
Increasing bolus dosing 243 
After the baseline recording, two 20-minute episodes followed in which two groups of 244 
rats (n=6 each) were injected with increasing doses of AP14145 (2.5 mg kg
-1
 and 5.0 245 
mg kg
-1
) or equivalent volumes of vehicle (50% PEG-400 and 50% saline). The 246 
injection time was 30 seconds. AERP was measured 1, 5, 10 and 15 minutes after the 247 
start of each injection. 248 
Constant rate infusion of AP14145 249 
After the baseline recording, a third group of rats received a constant rate infusion of 40 250 
mg kg
-1
 h
-1
 AP14145 over 20 minutes followed by a 20-minute post-infusion period. In 251 
these animals the AERP was measured every 2 minutes during and after infusion. 252 
Beam walk test - assessment of motor balance and coordination in mice 253 
A beam walk test was performed in mice in order to assess CNS exposure of KCa2 254 
inhibitors in vivo.  The mouse beam walk test is a validated test for addressing motor 255 
function (Brooks and Dunnett, 2009). Three groups of 1-2 months old male NMRI mice 256 
(Taconic Biosciences, USA) weighing 23-49 g were used. The mice were randomly 257 
assigned to either the vehicle control group, a 10 mg kg
-1 
NS8593 or a 10 mg kg
-1
 258 
AP14145 group. The mice were placed on a 1 meter wooden beam (ø 12 mm) and 259 
briefly trained in crossing the beam. After training, a 1 minute baseline recording was 260 
initiated and the number of falls and slips were noted. Hereafter the mice were 261 
randomly assigned to receive KCa2 inhibitors or vehicle (50% PEG-400 and 50% saline) 262 
by i.v. bolus injection in the tail vein. The mouse was observed immediately after 263 
injection for any behavioural changes. If any adverse effects occurred, the mouse was 264 
euthanized. Otherwise the mice were observed for behavioural changes and challenged 265 
with the beam walk 12 minutes post injection. All experiments were documented by 266 
video recordings. 267 
Data analysis  268 
Data was extracted from PatchMaster and analysed using GraphPad Prism 7.  269 
To calculate the IC50 value of AP14145, the measured currents were first normalized. 270 
Recorded currents without the presence of the drug were used as baseline and currents 271 
recorded at the highest tested concentration of AP14145 (30 µM L
-1
) were used as total 272 
inhibition of the channel. Individual IC50 values for each experiment were calculated 273 
using the equation: 274 
       
           
             
 
where X is the log of dose of AP14145 and Y is the normalized measured current. In all 275 
cases a Hill slope of -1.0 was considered. Individual IC50 values were later used to 276 
obtain the final x  ± SEM. IC50. The individual IC50 values were then used in student’s t-277 
tests to determine subtype selectivity.  278 
To calculate the EC50 of calcium, the values were normalized using the currents 279 
recorded at the lowest calcium concentration (0.01 µM L
-1
) for total inactivation and at 280 
the highest calcium concentration (30 µM L
-1
) for maximum activation of the channel. 281 
Individual EC50 values for each experiment were calculated using the equation: 282 
       
           
                         
 
where X is the log of dose of calcium and Y is the normalized measured current with 283 
variable Hill slope. Individual EC50 values were used to determine the final x  ± SEM 284 
EC50. 285 
Currents were also normalized to assess and compare the inhibitory effect of 10 µM L
-1 286 
AP14145 on HEK cells expressing KCa1.1, KCa2.1, KCa2.2, KCa2.3, KCa2.3 S508T 287 
A532V, KCa3.1 or KCa3.1 T250S V275A. For each individual cell, 0% current was 288 
defined as 0 nA and 100% current was defined as the current recorded in the absence of 289 
the compound.  he final results are summarized as x     EM of the individual values  290 
To quantify and compare the activation and inhibition effects of 10 µM L
-1 
NS309 and 291 
10 µM L
-1 
AP14145 on the KCa2.3 channel, values were normalized for each individual 292 
cell. In this case, 0 was defined as 0 nA and currents recorded in the absence of both 293 
compounds were defined as 1.  hese individual values were used to calculate the final x  294 
± SEM. 295 
The last ten data points obtained after the application of a new compound or solution 296 
and corresponding to the steady state were used to create every single value.  297 
Student’s t-test was performed to assess statistical significance of the effect of 298 
AP14145. P values < 0.05 were considered significant.  299 
Physicochemical properties of AP14145 and NS8593 were calculated using the Instant 300 
JChem (ChemAxon) software. 301 
Perfused rat heart data and closed chest continuous data are summarized using the x  ± 302 
SEM. A one-way ANOVA with  ukey’s comparison post-test was used to compare the 303 
effect of paxilline and AP14145 on the isolated rat heart. Multiple t tests with Holm-304 
 idak’s correction for multiple comparisons were used to compare AERP differences 305 
between the group of rats that received AP14145 as increasing bolus doses and the time 306 
matched control group at matching time points.  Multiple t tests with Holm- idak’s 307 
correction for multiple comparisons were used to compare each AERP-value during and 308 
after infusion to the mean baseline AERP values. P values < 0.05 were considered 309 
significant. 310 
Nomenclature of Targets and Ligands  311 
Key protein targets and ligands in this article are hyperlinked to corresponding entries in 312 
http://www.guidetopharmacology.org, the common portal for data from the 313 
IUPHAR/BPS Guide to PHARMACOLOGY (Southan et al., 2016), and are 314 
permanently archived in the Concise Guide to PHARMACOLOGY 2015/16 (Alexander 315 
et al., 2015). 316 
 317 
Results 318 
AP14145 inhibits both hKCa2.2 and hKCa2.3 currents with equal potency 319 
Using inside-out manual patch clamp we tested AP14145 on both the hKCa2.2 and 320 
hKCa2.3 channels. Once the patch was excised, the channels were exposed to the bath’s 321 
intracellular solution, containing 400 nM L
-1
 free [Ca
2+
]. In symmetrical intra- and 322 
extra-cellular K
+
 solutions, hKCa2.3 currents displayed a characteristic inwardly 323 
rectifying current-voltage relationship (Fig 2a). Currents were elicited using voltage 324 
ramps from -80 mV to +80 mV applied every 2 seconds. Once the hKCa2 current was 325 
stable, up to 8 increasing concentrations of AP14145 between 0.01 - 30 µM L
-1
 were 326 
applied and perfused by gravity flow on the patch (Fig 2b). For each concentration the 327 
drug was applied until steady state was reached.  328 
AP14145 was able to inhibit both hKCa2.2 and hKCa2.3 in a concentration-dependent 329 
fashion (Fig 2b, data not shown for hKCa2.2). The effect started at nanomolar 330 
concentrations and total inhibition was reached at 30 µM L
-1
 (Fig 2b). Calculated IC50 331 
for AP14145 on both the hKCa2.2 and hKCa2.3 was 1.1 ± 0.3 µM L
-1
 (n = 7 each, Fig 332 
2c), with a fixed Hill slope of -1.0. The drug consequently did not display any subtype 333 
selectivity between hKCa2.2 and hKCa2.3.  334 
Additionally, the inhibitory effect of AP14145 was also tested on the hKCa1.1, hKCa2.1 335 
and hKCa3.1 channels using whole cell patch clamp for further selectivity assessment 336 
(Fig 3). The application of 10 µM L
-1 
AP14145 inhibited 50 ± 10% of the hKCa1.1 337 
current (n = 6) and 90 ± 4% of the hKCa2.1 current (n = 7). In contrast, hKCa3.1 currents 338 
were not significantly affected by the application of 10 µM L
-1 
AP14145 (n = 8). 339 
AP14145 modifies hKCa2.3 calcium sensitivity 340 
To establish how AP14145 inhibits the channel, we performed inside out patch clamp 341 
recordings to assess the effect of the drug on the calcium sensitivity of the hKCa2.3 342 
channel. Patches were excised from HEK cells stably expressing the hKCa2.3 channel 343 
and currents elicited using voltage ramps. We exposed the patches to eight different free 344 
Ca
2+
 concentrations and calculated the EC50 for calcium activation of the channel in the 345 
absence and presence of 10 µM L
-1
 AP14145 (Fig 4a and b). Free calcium 346 
concentrations ranged from 0.01 - 30 µM L
-1
 and were perfused using gravity flow. 347 
Solutions were applied until steady state was reached.  348 
In the absence of AP14145, hKCa2.3 channels were fully activated at 3 µM L
-1
 of 349 
intracellular Ca
2+
 (Fig 4a), but in the presence of 10 µM L
-1
 AP14145, up to 10 µM L
-1
 350 
were needed to reach total activation of the channel (Fig 4b). At a 10 µM L
-1
 351 
concentration, the drug shifted the calcium-activation curve of the KCa2.3 channel to the 352 
right (Fig 4c), so higher calcium concentrations were needed to activate the channels. 353 
This was also shown by the significantly increased EC50 of Ca
2+
 from 0.36 ± 0.02 µM L
-
354 
1
 (n = 9) to 1.3 ± 0.2 µM L
-1
 (n = 7). Most prominently, the Hill coefficients were also 355 
significantly modified by the presence of AP14145 from 5.2 ± 0.3 to 1.2 ± 0.1 (absence 356 
of AP14145 vs. 10 µM L
-1
 AP14145). 357 
AP14145 reverses the effect of the positive KCa2 gating modulator NS309 358 
The inhibitory effect of AP14145 was also studied in the presence of a high 359 
concentration of the KCa2 positive gating modulator NS309. Patches excised from HEK 360 
cells stably expressing the hKCa2.3 channel were exposed to 400 nM L
-1
 free [Ca
2+
] 361 
intracellular solution. After stabilisation of the baseline, 10 µM L
-1
 NS309 were applied 362 
on the patch, further activating the channel and  increasing hKCa2.3 current by 4 ± 1 fold 363 
(n = 7, Fig 5). When steady state was reached, 10 µM L
-1
 AP14145 were added to the 364 
bath, in the continued presence of NS309. The application of AP14145 reduced hKCa2.3 365 
current to values close to the control baseline, reversing the positive gating effect of 366 
NS309 (Figure 5). Furthermore, in the presence of 10 µM L
-1
 NS309, total current 367 
inhibition by 10 µM L
-1
 AP14145 was significantly diminished from 80 ± 3% (n = 7) to 368 
61 ± 4% (n = 7, Fig 5). 369 
AP14145 inhibition strongly depends on two amino acids, S508 and A533, located in 370 
the inner pore of the channel 371 
To establish possible molecular determinants of rKCa2.3 inhibition by AP14145 we 372 
mutated two amino acids, S508 and A533 (corresponding to S507 and A532 in 373 
hKCa2.3), located in the inner pore of the channel and known to confer sensitivity to the 374 
negative allosteric modulator of KCa2 channels, NS8593 (Jenkins et al., 2011).  375 
Whole-cell patch clamp experiments were conducted on transiently transfected HEK 376 
cells with either the WT rKCa2.3 channel or the rKCa2.3 S508T A533V mutant. The 377 
channels were activated by 400 nM L
-1
 free [Ca
2+
] intracellular solution and currents 378 
were elicited using voltage ramps. Again, in symmetrical intra- and extra-cellular K
+
 379 
solutions, WT rKCa2.3 currents displayed a characteristic inwardly rectifying current-380 
voltage relationship (Fig 6a). In contrast to the WT rKCa2.3 channel, the maximum 381 
current normalized to cell capacitance of the mutant rKCa2.3 was significantly reduced 382 
(WT: 650 ± 96 pA/pF vs. mutant: 87 ± 23 pA/pF, n = 7 each, Fig 6b). Rectification, 383 
determined as the ratio of the current amplitude at – 80 and + 80 mV, was also changed 384 
by the mutation, from 9 ± 1 I-80/I+80 in the WT to 2.9 ± 0.4 I-80/I+80 in the mutant. These 385 
observations are in agreement with what was previously described by Jenkins et al., 386 
2011. After current stabilisation, 10 µM L
-1
 of AP14145 were applied on the cell 387 
transfected with the WT or the mutant protein for 1 - 2 min or until a steady state drug 388 
effect was reached (Fig 6a and b).  389 
The experiments showed that, while rKCa2.3 currents recorded from cells transfected 390 
with the WT channel were strongly inhibited by application of 10 µM L
-1
 AP14145 (Fig 391 
6a), currents recorded from cells transfected with the mutant rKCa.2.3 were only 392 
partially affected by the presence of the compound (Fig 6b). The inhibitory effect of 393 
AP14145 was statistically different between the WT and the mutant when analysed as 394 
the relative current inhibition after application of AP14145 (95 ± 1 % and 22 ± 6 % 395 
inhibition, WT rKCa2.3 vs rKCa2.3 S508T A533V, n = 7 each, Fig 6e). 396 
To ensure that S508 and A533 are important for AP14145 sensitivity, we introduced 397 
these amino acids in their homologous positions in the AP14145 insensitive KCa3.1 398 
channel, T250 and V275, respectively. The KCa3.1 T250S V275A mutant was tested 399 
using whole cell patch clamp to determine its sensitivity to AP14145. After activation 400 
of the channel with 400 nM L
-1
 free [Ca
2+
] intracellular solution and current 401 
stabilization, 10 µM L
-1
 AP14145 was applied on the cell. In contrast to the KCa3.1 WT 402 
channel (Fig 6c), the mutant KCa3.1 current was inhibited by 92 ± 1 % (n =7, Fig 6d), 403 
comparable to the inhibitory effect observed on rKCa2.3.  404 
AP14145 increases the duration of the atrial effective refractory period in isolated 405 
perfused rat hearts 406 
Excised rat hearts were connected to a retrograde perfusion Langendorff setup to 407 
measure the effect of AP14145 on the AERP and discard any KCa1.1 mediated effects. 408 
Once a stable baseline was achieved, the hearts were perfused first with 1 µM L
-1
 of the 409 
KCa1.1 inhibitor paxilline. Twenty minutes later, the dose of paxilline was increased to 3 410 
µM L
-1
 for 20 more minutes. Finally, after a 20 minute wash period, 10 µM L
-1
 of 411 
AP14145 were perfused into the heart.  412 
Paxilline did not affect the AERP in any of the tested doses, but AP14145 was able to 413 
prolong the AERP significantly, from 19 ± 3 ms to 57 ± 12 ms (n = 5, Fig. 7).  414 
AP14145 increases the duration of the atrial effective refractory period in rats 415 
To investigate the in vivo effects of AP14145, 6 male rats received AP14145 in 416 
increasing doses (2.5 mg kg
-1
 and 5 mg kg
-1
) and 6 time matched control rats received 417 
corresponding volumes of vehicle (0.5 ml kg
-1
 and 1 ml kg
-1
, respectively).  418 
One minute after injection of 2.5 mg kg
-1
 AP14145 the AERP was significantly 419 
increased from 37 ± 2 ms in the time matched control group to 53 ± 6 ms (Fig. 8a). The 420 
AERP returned towards baseline values, and five minutes after the injection of 2.5 mg 421 
kg
-1
 the AERP was no longer significantly different from that of the time matched 422 
controls. One minute after injection of 5 mg kg
-1
 AP14145 the AERP was significantly 423 
increased from 31 ± 2 ms in the time matched control group to 58 ± 8 ms (Fig. 8a). 424 
Again, the AERP returned towards baseline values, and ten minutes after the injection 425 
of 5 mg kg
-1
 the AERP was no longer significantly different from that of the time 426 
matched controls. 427 
A third group of rats (n = 6) received a constant rate infusion of 40 mg kg
-1
 h
-1
 over 20 428 
minutes and were monitored for an additional 20 minutes after infusion (Fig 8b). In 429 
these rats the AERP was significantly increased compared to baseline values from 4 430 
minutes after the infusion started (i.e. after a cumulative dose of 2.7 mg kg
-1
). The 431 
AERP continued to increase during the rest of the infusion and returned towards 432 
baseline values after infusion. 433 
AP14145 does not impair motor coordination in mice 434 
A beam walk test was performed in mice in order to assess CNS exposure of KCa2 435 
inhibitors in vivo. Three groups of male NMRI mice were used, a vehicle control group 436 
(30.5 ± 0.3 g, n = 6), a 10 mg kg
-1 
NS8593 (26 ± 1 g, n = 3) and a 10 mg kg
-1
 AP14145 437 
group (36 ± 5 g, n = 6).  438 
Shortly after the injection of 10 mg kg 
-1
 NS8593, all mice showed severe convulsions 439 
making them unable to walk on the beam (Fig 9). Therefore, the mice were euthanized 440 
by cervical dislocation and the experiment was terminated. 441 
In contrast, when mice were injected with AP14145, no acute effects were observed and 442 
the beam walk test was performed 12 minutes after dosing. The mice did not slip or fall 443 
from the beam in either of the two tests and no behavioural changes were observed. 444 
These observations were not different to the ones from the vehicle control group (Fig 9). 445 
 446 
Discussion 447 
KCa2 channels are inwardly rectifying potassium channels (Köhler et al., 1996) widely 448 
distributed in humans, both in the CNS and peripheral tissues (Chen et al., 2004). In the 449 
heart, they play an important role in the late repolarization phase of the atria (Li et al., 450 
2009). Moreover, it has been demonstrated that inhibition of KCa2 channels prolongs the 451 
AERP  (Diness et al., 2010; Skibsbye et al., 2011; Qi et al., 2014; Haugaard et al., 452 
2015). Therefore, the KCa2 channel is considered a promising new target to treat AF. 453 
Here we present a new KCa2 inhibitor, AP14145, which could constitute an important 454 
tool in rodents, to target and study the inhibition of peripheral KCa2.x channels in vivo.  455 
In initial experiments it was established that AP14145 inhibits hKCa2.2 and hKCa2.3 in 456 
an equipotent manner with IC50 values of 1.1 ± 0.3 µM L
-1
. To determine the 457 
mechanism of inhibition of AP14145, we conducted inside-out patch clamp 458 
experiments. Patches were excised from HEK 293 cells stably expressing the hKCa2.3 459 
channel and exposed to a range of intracellular solutions with different free calcium 460 
concentrations. Calcium activation was assessed in the absence and presence of 461 
AP14145. The compound significantly increased the EC50 of Ca
2+
 from 0.36 ± 0.02 µM 462 
L
-1
 to 1.3 ± 0.2 µM L
-1
, thereby shifting the Ca
2+
 activation curve of KCa2 channel 463 
activation to higher values. The Hill coefficients were also modified by the presence of 464 
AP14145 from 5.2 ± 0.3 to 1.2 ± 0.1 (absence of AP14145 vs. 10 µM L
-1
 AP14145). 465 
These results suggest that the drug modifies the channel’s calcium sensitivity and acts 466 
as a negative allosteric modulator, very similar to the previously reported NS8593. The 467 
change of the Hill coefficient may also indicate a loss of calcium cooperativity which 468 
may impede calcium binding. Moreover, the inhibitory effect of AP14145 was studied 469 
in the presence of the KCa2.x  positive allosteric modulator NS309, which is known to 470 
increase the  calcium sensitivity of the channel (Strøbæk et al., 2004). In these 471 
experiments, AP14145 was able to reverse NS309-mediated KCa2.3 channel activation, 472 
suggesting a functional competition between the two compounds and further supporting 473 
the negative allosteric mechanism of AP14145.    474 
In the study by Jenkins et al. in 2011, the binding site of NS8593, another KCa2 negative 475 
allosteric modulator, was found to be located at the inner pore of the channel. This was 476 
an interesting finding since the drug had previously been found to decrease calcium 477 
sensitivity of the channel and could be speculated to locate the binding site at the C-478 
terminal domain, close to the calmodulin binding domain. Instead, binding interacts 479 
with two specific amino acids S507 and A532, located on helixes S5 and S6, 480 
respectively. When these two amino acids were mutated to the corresponding residues 481 
found on the closely related KCa3.1 channel, which is not inhibited by NS8593, they 482 
obtained a KCa2.3 mutant resistant to the effect of the drug, with preserved channel 483 
confirmation and calcium sensitivity. In order to find out if AP14145 and NS8593 484 
shared the same binding site, we conducted whole cell patch clamp experiments on 485 
transiently transfected HEK cells with rKCa2.3 WT or rKCa2.3 S508T A533V, 486 
corresponding to S507 and A532 in the hKCa2.3 channel. While the WT current was 487 
strongly inhibited using 10 µM L
-1
 AP14145, the NS8593 resistant mutant was only 488 
partially affected by the presence of the drug, suggesting that S508 and A533 are 489 
important also for AP14145 inhibition. The loss of AP14145 sensitivity in rKCa2.3 490 
S508T A533V cannot be explained by differences in calcium-activation or channel 491 
conformation as these characteristics are preserved in the mutant (Jenkins et al., 2011). 492 
AP14145 and NS8593 are structurally close analogues (Fig 1) and these experiments 493 
demonstrate that AP14145 and NS8593 appear to share the same inhibition mechanism 494 
as well as some of their binding determinants. Finally, to confirm that S507 and A532 495 
are important for the inhibitory effect of AP14145 on KCa2.3 we introduced these amino 496 
acids in their homologous positions on the insensitive KCa3.1 channel. With the addition 497 
of these two amino acids, AP14145 sensitivity was fully restored in the KCa3.1 channel 498 
(Fig 6), further demonstrating that S507 and A532 are important for AP14145 499 
inhibition. KCa2 channels are widely expressed in the brain, including the cerebellum 500 
(Stocker and Pedarzani, 2000), where they contribute to the action potential 501 
afterhyperpolarization (Hosy et al., 2011). It has further been demonstrated that 502 
inhibition of KCa2.2 channels in cerebellum disturbs the motor output which is revealed 503 
as ataxia or convulsion like phenotype especially apparent in the hind legs (Alvina and 504 
Khodakhah, 2010). As an indication of CNS exposure and inhibition of central KCa2 505 
channels a beam walk test was performed. The test is designed to assess impaired motor 506 
coordination and balance in mice. 507 
Mice injected intravenously with 10 mg kg
-1
 NS8593 immediately showed acute CNS 508 
effects in the form of convulsions, and consequently were euthanized. In contrast i.v. 509 
injection of 10 mg kg
-1
 AP14145 had no apparent CNS effects, and the mice were able 510 
to cross the beam without slipping or falling from the beam, similarly to the vehicle 511 
control mice. Importantly, NS8593 plasma protein binding is higher than AP14145 512 
(95.38% vs. 91.35% bound, respectively, Table 1), meaning that a higher amount of 513 
AP14145 is freely available in plasma compared to NS8593 when the same dose of both 514 
compounds is injected. Moreover, we found that i.v. injection of 2.5 mg kg
-1
 AP14145 515 
significantly increases the atrial refractoriness in rats within 1 min of injection, 516 
suggesting that 10 mg kg
-1
 is sufficient to peripheral KCa2 target engagement.  517 
A possible explanation for the apparent difference in CNS penetration of the two 518 
compounds lies in their structure (Fig 1) and physicochemical properties (Table 1). In 519 
particular, AP14145 contains a carboxamide moiety on the bicyclic benzimidazole ring, 520 
a chemical moiety that adds polarity to the molecule and is known to be a common 521 
substrate for P-glycoprotein transporter mediated efflux. The calculated polar surface 522 
area (PSA) of AP14145 is 70, which is significantly higher than NS8593 (Table 1), 523 
indicating a lower likelihood of penetrating the blood-brain barrier. It can thus be 524 
hypothesised that the structural features in AP14145 make the compound less likely to 525 
penetrate to induce CNS mediated convulsions when compared to NS8593. Although 526 
this difference in profile could in principle be caused by differences in the 527 
pharmacokinetic profile of the two compounds, this seems an unlikely explanation, 528 
since, as has been shown in Diness et al. (2010), 5 mg kg
-1
 of NS8593 cause similar 529 
increases of the AERP in rats when compared to the effect of 5 mg kg
-1
 of AP14145 530 
(Fig 8a).  531 
High concentrations of AP14145 (10 µM L-1) significantly inhibited the KCa1.1 532 
channel. However, as paxilline, which is a well-known specific inhibitor of KCa1.1 533 
channels (Nardi and Olesen, 2008), did not have any effect on the atrial refractoriness of 534 
isolated perfused rat hearts, we conclude that the inhibition of KCa1.1 by AP14145 does 535 
not contribute to the AERP prolonging effects of AP14145. This is in accordance with 536 
studies demonstrating the lack of KCa1.1 channels and currents in the plasma membrane 537 
of cardiomyocytes (Bautista et al., 2009; Singh et al., 2013).  538 
The apparent reduced CNS exposure of the drug makes AP14145 a unique and useful 539 
new tool compound that allows the study of peripheral KCa2 inhibition without 540 
apparently interfering with CNS function in awake rodents. This might help further 541 
development and understanding of the cardiac and endothelial role of KCa2 in a number 542 
of physiological and pathological settings.  543 
 544 
Conclusions 545 
In this work we present the novel KCa2 negative gating modulator AP14145. This new 546 
drug inhibits both the hKCa2.2 and hKCa2.3 with equal potency (IC50 = 1.1 ± 0.3 μM L
-1
 547 
with 400 nM L
-1
 intracellular Ca
2+
) by decreasing the calcium sensitivity of the channel. 548 
The inhibitory effect of AP14145 effect is strongly dependent on two amino acids, S508 549 
and A533 in the rKCa2.3, located in the inner pore of the channel. In vivo, AP14145 550 
significantly increases the atrial refractoriness in rats shortly after a 2.5 mg kg
-1
 or 5.0 551 
mg kg
-1
 bolus injection. In contrast to NS8593, a dose of 10 mg kg
-1
 of AP14145 did not 552 
trigger any apparent acute CNS mediated effects in mice, suggesting that the compound 553 
does not penetrate the blood brain barrier to the same degree as NS8593 in rodents. This 554 
key difference could for the first time allow for the use of a KCa2 negative modulator in 555 
vivo without interfering with CNS function. We expect this feature might help further 556 
development and understanding of the cardiac and endothelial role of KCa2 channels. 557 
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Figures and figure legends 691 
 692 
Fig. 1. Chemical structures of AP14145 (left) and NS8593 (right).  693 
 694 
Fig. 2. a) Representative current-voltage recordings of the inhibition of hKCa2.3 by 695 
increasing concentrations of the drug AP14145 and b) its current-time plot obtained by 696 
inside-out patch clamp on HEK cells stably expressing the channel. c) Inhibition curves 697 
of AP14145 on both the hKCa2.2 (n = 7) and hKCa2.3 ( n = 7) channel. 698 
 699 
 700 
 701 
Fig. 3. Inhibitory effect of 10 µM L
-1
 AP14145 on KCa1.1, KCa2.1, KCa2.2, KCa2.3 and 702 
KCa3.1 channels. All measurements were obtained by whole cell patch clamp except 703 
KCa2.2, which were obtained by inside-out patch clamp.  704 
 705 
Fig. 4. Representative current-voltage plots (left) and their corresponding current-time 706 
plots (right) of hKCa2.3 calcium activation a) in the absence of AP14145 and b) in the 707 
presence of 10 µM L
-1
 AP14145. c) Calcium activation curves for the hKCa2.3 channel 708 
in the absence of AP14145 (red curve, n = 9) and in the presence of 10 µM L
-1
 709 
AP14145 (black curve, n = 7).  710 
 711 
Fig. 5. Representative current-voltage plot (left) and its corresponding current-time plot 712 
(centre) of the effect of 10 µM L
-1
 NS309 in the absence and in the presence of 10 µM 713 
L
-1
 AP14145 on excised hKCa2.3 patches. On the right, bar graph comparing the effects 714 
of 10 µM L
-1
 AP14145 (n = 7), 10 µM L
-1
 NS309 (n = 7), and 10 µM L
-1
 AP14145 + 10 715 
µM L
-1
 NS309 (n = 7) on excised hKCa2.3 patches. 716 
 717 
Fig. 6. Representative current-voltage plots (left) and current-time plots (right) 718 
depicting the effect of AP14145 10 µM L
-1
 on HEK cells transiently transfected with a) 719 
rKCa2.3 WT, b) rKCa2.3 S508T A533V, c) hKCa3.1 WT and d) hKCa3.1 T250S V275A 720 
recorded using whole cell patch clamp. e) Bar graph comparing the inhibitory effect of 721 
10 µM L
-1
 AP14145 on rKCa2.3 WT (n = 7), rKCa2.3 S508T A533V (n = 7), hKCa3.1 722 
WT channel (n = 8) and hKCa3.1 T250S V275A (n = 7). 723 
 724 
Fig 7. Effect of 1 µM L
-1
 and 3 µM L
-1 
of the KCa1.1 inhibitor paxilline and 10 µM L
-1
 725 
AP14145 on the AERP of isolated perfused rat hearts (n = 5). 726 
 727 
Fig. 8. Effects on AERP in closed chest in vivo rats: a) Bolus doses of 2.5 mg kg
-1
 and 5 728 
mg kg
-1
 AP14145 significantly increased the AERP compared to time matched controls 729 
receiving corresponding volumes of vehicle. b) AP14145 given as a constant rate 730 
infusion of 40 mg kg
-1 
h
-1
 over 20 minutes increased AERP compared to the baseline 731 
average and returned towards baseline values post-infusion. 732 
 733 
Fig. 9. Bar graph depicting the amount of convulsions triggered by the administration of 734 
the vehicle, 10 mg kg 
-1
 AP14145 and 10 mg kg 
-1
 NS8593. 735 
 736 
Table 1. Calculated physicochemical properties and plasma protein binding (PPB) of 737 
NS8593 and AP14145. 738 
 739 
 740 
 741 
 log D (pH 7.4) log P PSA (Å²) PPB (% bound) 
NS8593 4.0 4.1 41 95.38 
AP14145 3.6 3.7 70 91.35 
